Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
April 2014—Qiagen announced the launch plans of products designed to reduce the challenges of bottlenecks in next-generation sequencing: sample preparation and bioinformatics. The products add to Qiagen’s portfolio of solutions designed to run with any NGS platform.
April 2014—Dako and Amgen will develop a molecular diagnostic test using Dako’s IQFISH hybridization buffer.
April 2014—Audit MicroControls added to its line of products the Control LQ Glycohemoglobin A1c—a liquid bi-level reference control consisting of human blood–based solutions.
April 2014—Dako entered into a master framework agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline.
April 2014—Vector Laboratories’ Avidin-HRP and Streptavidin-HRP are optimized to yield high signal-to-noise ratios in solid phase assays, such as ELISAs and blotting applications.
April 2014—AutoGenomics launched the Infinity High Throughput System, which provides semiautomated multiplexed DNA analysis in an open front-end system with a flexible and scalable throughput, from 96 to 3,456 samples tested in just one shift.
April 2014—PAML and CellNetix launched a joint venture anatomic pathology reference laboratory separately branded as Symbiodx. A major focus of this venture will be on molecular oncology with a broad offering of molecular tests, including next-generation sequencing, IHC, flow cytometry, and cytogenetics.
April 2014—Molecular Pathology Laboratory Network, of Maryville, Tenn., acquired the Illumina MiSeqDx, a next-generation sequencing system cleared by the FDA for targeted sequencing of human genomic DNA.
April 2014—UC San Francisco and Quest Diagnostics formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine for improved patient care, treatment, and outcomes.
April 2014—In a licensing agreement between Biomatrica and ATCC, Biomatrica will supply DNAstable and RNAstable reagents for the stabilization of DNA and RNA standards.
